Arrowstreet Capital
ALXN

Arrowstreet Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Arrowstreet Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,002,319
Closed -$184M – 2022
2021
Q2 		$184M Buy
1,002,319
+919,719
+1,113% +$158M 0.23% 86
2021
Q1 		$12.6M Buy
+82,600
New +$12.8M 0.02% 769
2020
Q3 		– Sell
-10,508
Closed -$1.18M – 2620
2020
Q2 		$1.18M Sell
10,508
-301,649
-97% -$32M ﹤0.01% 1703
2020
Q1 		$28M Buy
312,157
+197,657
+173% +$19.4M 0.08% 226
2019
Q4 		$12.4M Buy
+114,500
New +$12.2M 0.03% 540
2019
Q3 		– Sell
-13,300
Closed -$1.74M – 1792
2019
Q2 		$1.74M Buy
+13,300
New +$1.71M ﹤0.01% 941
2019
Q1 		– Sell
-203,200
Closed -$19.8M – 1959
2018
Q4 		$19.8M Buy
+203,200
New +$24M 0.05% 300
2018
Q3 		– Sell
-701,814
Closed -$87.1M – 1328
2018
Q2 		$87.1M Buy
701,814
+227,700
+48% +$26.6M 0.21% 110
2018
Q1 		$52.8M Buy
474,114
+163,214
+52% +$19.5M 0.12% 182
2017
Q4 		$37.2M Buy
310,900
+282,900
+1,010% +$34.5M 0.09% 218
2017
Q3 		$3.93M Sell
28,000
-20,700
-43% -$2.81M 0.01% 539
2017
Q2 		$5.92M Buy
48,700
+19,000
+64% +$2.21M 0.02% 439
2017
Q1 		$3.6M Buy
+29,700
New +$3.83M 0.01% 649
2016
Q3 		– Sell
-18,300
Closed -$2.14M – 1693
2016
Q2 		$2.14M Buy
+18,300
New +$2.6M 0.01% 816
2014
Q4 		– Sell
-207,571
Closed -$34.4M – 1372
2014
Q3 		$34.4M Buy
207,571
+132,104
+175% +$21.7M 0.18% 134
2014
Q2 		$11.8M Buy
75,467
+18,628
+33% +$2.94M 0.06% 274
2014
Q1 		$8.65M Buy
+56,839
New +$9.04M 0.05% 320
2013
Q3 		– Sell
-351,868
Closed -$32.5M – 1158
2013
Q2 		$32.5M Buy
+351,868
New +$33.9M 0.24% 101

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Arrowstreet Capital's ALXN Position: Q3 2021 in Review

Arrowstreet Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,002,319 shares — an estimated $184M sold.

Arrowstreet Capital first reported a position in ALXN in Q2 2013 and held it in 18 quarters. The position peaked at $184M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Arrowstreet Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 1,002,319 Alexion Pharmaceuticals shares in Q3 2021, an estimated $184M.
  • Arrowstreet Capital first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Arrowstreet Capital's Alexion Pharmaceuticals position peaked at $184M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Arrowstreet Capital's 13F filing for Q3 2021, filed 12 Nov 2021.